GT
CRBP icon

Glenmede Trust’s Corbus Pharmaceuticals CRBP Stock Holding History

Glenmede Trust’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13
Closed – – 1440
2020
Q3 		$0 Hold
13
– – ﹤0.01% 2484
2020
Q2 		$3K Buy
13
+8
+160% +$1.62K ﹤0.01% 2171
2020
Q1 		$0 Hold
5
– – ﹤0.01% 3016
2019
Q4 		$0 Hold
5
– – ﹤0.01% 3029
2019
Q3 		$0 Hold
5
– – ﹤0.01% 3030
2019
Q2 		$1 Hold
5
– – ﹤0.01% 2948
2019
Q1 		$1 Hold
5
– – ﹤0.01% 2918
2018
Q4 		$0 Buy
+5
New +$998 ﹤0.01% 3027
2017
Q4 		– Sell
-5
Closed -$1K – 2689
2017
Q3 		$1K Buy
+5
New +$978 ﹤0.01% 2645

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust's CRBP Position: Q4 2020 in Review

Glenmede Trust sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 13 shares.

Glenmede Trust first reported a position in CRBP in Q3 2017 and held it in 9 quarters. The position peaked at $3K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

  • Glenmede Trust reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 13 Corbus Pharmaceuticals shares in Q4 2020.
  • Glenmede Trust first reported a position in Corbus Pharmaceuticals in Q3 2017 and held it in 9 quarters.
  • Glenmede Trust's Corbus Pharmaceuticals position peaked at $3K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.